Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27186250 | 0.83 | DGAT1 (0.32) | DGAT1MAPTNPC1 | |
| SCHEMBL31219625 | 0.78 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL20155347 | 0.75 | MAT2A (0.38) | MAPTNPC1PDE4D | |
| SCHEMBL20155042 | 0.75 | MAP4K4 (0.42) | PDE4D | |
| SCHEMBL5591621 | 0.75 | SYK (0.34) | MAPT | |
| SCHEMBL30546510 | 0.75 | HDAC8 (0.36) | DGAT1NPC1 | |
| SCHEMBL5283777 | 0.75 | NPC1 (0.36) | DGAT1MAPTNPC1 | |
| SCHEMBL25323155 | 0.74 | DGAT1 (0.37) | DGAT1NPC1 | |
| SCHEMBL12570889 | 0.73 | TP53 (0.31) | NPC1 | |
| SCHEMBL31741718 | 0.73 | DGAT1 (0.35) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074906-A1 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-06 | — | — | US | disclosed |
| EP-4450502-A1 | AZAINDOLE DERIVATIVE INHIBITING H-PGDS | Sato Pharmaceutical Co., Ltd. (JP) | 2024-10-23 | — | — | EP | disclosed |
| CN-118401522-A | Azaindole derivatives inhibiting H-PGDS | 佐藤制药株式会社 | 2024-07-26 | — | — | CN | disclosed |
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2023113023-A1 | AZAINDOLE DERIVATIVE INHIBITING H-PGDS | 佐藤製薬株式会社 | 2023-06-22 | — | — | WO | disclosed |
| WO-2022187266-A1 | NOVEL SUBSTITUTED BICYCLI AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074906-A1 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | HPGDS, PTGIS, HPGD | DGAT1 820/4885MAPT 4870/4885NPC1 3570/4885 |
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | SOS1, SOS2, KSR1 | DGAT1 3718/4885MAPT 4302/4885NPC1 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.